Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim E. | - |
dc.contributor.author | Lim E.-K. | - |
dc.contributor.author | GEUNSEON PARK | - |
dc.contributor.author | CHAEWON PARK | - |
dc.contributor.author | JONG-WOO LIM | - |
dc.contributor.author | Hyo Lee | - |
dc.contributor.author | Na W. | - |
dc.contributor.author | Yeom M. | - |
dc.contributor.author | JINYOUNG KIM | - |
dc.contributor.author | Song D. | - |
dc.contributor.author | SEUNGJOO HAAM | - |
dc.date.accessioned | 2021-11-30T10:40:48Z | - |
dc.date.available | 2021-11-30T10:40:48Z | - |
dc.date.created | 2021-11-24 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.uri | https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/5251 | - |
dc.description.abstract | While the coronavirus disease (COVID-19) accounts for the current global pandemic, the emergence of other unknown pathogens, named “Disease X,” remains a serious concern in the future. Emerging or re-emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever-increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting-edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano-based products is presented. Finally, to conclude, the development of a nanomaterial-based system using a “One Health” approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-V C H VERLAG GMBH | - |
dc.title | Advanced Nanomaterials for Preparedness Against (Re-)Emerging Viral Diseases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | GEUNSEON PARK | - |
dc.contributor.affiliatedAuthor | CHAEWON PARK | - |
dc.contributor.affiliatedAuthor | JONG-WOO LIM | - |
dc.contributor.affiliatedAuthor | Hyo Lee | - |
dc.contributor.affiliatedAuthor | JINYOUNG KIM | - |
dc.contributor.affiliatedAuthor | SEUNGJOO HAAM | - |
dc.identifier.doi | 10.1002/adma.202005927 | - |
dc.identifier.scopusid | 2-s2.0-85101437978 | - |
dc.identifier.bibliographicCitation | ADVANCED MATERIALS, v.33, no.47, pp.2005927-1 - 2005927-32 | - |
dc.relation.isPartOf | ADVANCED MATERIALS | - |
dc.citation.title | ADVANCED MATERIALS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 47 | - |
dc.citation.startPage | 2005927-1 | - |
dc.citation.endPage | 2005927-32 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | Nanomaterials | - |
dc.subject.keywordAuthor | Advanced Nanomaterials | - |
dc.subject.keywordAuthor | Viral diseases | - |
dc.subject.keywordAuthor | One health | - |
Items in Scholar Hub are protected by copyright, with all rights reserved, unless otherwise indicated.
Yonsei University 50 Yonsei-ro Seodaemun-gu, Seoul, 03722, Republic of Korea 1599-1885
© 2021 YONSEI UNIV. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.